Business Wire

MILREM-ROBOTICS

14.9.2021 09:02:12 CEST | Business Wire | Press release

Share
Milrem Robotics to Develop the Nordic Robotic Wingman With Kongsberg Defence & Aerospace

The leading European robotics and autonomous systems developer Milrem Robotics is to develop a new Robotic Combat Vehicle (RCV) named Nordic Robotic Wingman in cooperation with the leading technology and defence supplier, Kongsberg Defence & Aerospace (KONGSBERG).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005044/en/

The Nordic Robotic Wingman will be based on Milrem Robotics’ state of the art Type-X RCV and KONGSBERG’s latest and best PROTECTOR Remote Turrets (RT) that will be chosen specifically to meet the particular needs of various end-users.

The first Nordic Robotic Wingman concept will be exhibited at DSEI 2021 in London.

“Milrem Robotics and KONGSBERG have agreed to jointly continue the development of the Type-X RCV by integrating KONGSBERG’s systems to address the requirements of many countries interested in this type of technology, especially the Nordics and Western Europe, but also the US,” said Sverker Svärdby, Managing Director of Milrem Robotics’ Sweden. “Combining our knowledge of robotic combat vehicles and KONGSBERG’s wide range of systems and extensive expertise in defence systems development, we are capable of providing world-class systems based on customer needs,” Svärdby added.

The Type-X provides equal or overmatching firepower and tactical usage to a unit equipped with Infantry Fighting vehicles and gives mechanized units the means to breach enemy defensive positions with minimal risk to own troops. It can be fitted with a cannon up to 50 mm, anti-tank missiles and a tethered drone for continuous situational awareness.

“KONGSBERG has a family of unmanned PROTECTOR Remote Weapon Systems, ranging from the smallest RS2 Remote Weapon Station to the true Infantry Fighting Vehicle turret RT60 with Anti-Tank Guided Missile capability. The systems have a common software baseline, are easy to integrate and provide proven capabilities for the warfighter. KONGSBERG’s solution provides the operator with situational awareness and a safe and secure network-based fire control that is fielded with the Norwegian Army and in delivery to the US Army’s Robotic Combat Vehicle program,” said Arne Gjennestad, Vice President of Marketing & Sales, KONGSBERG.

Milrem Robotics’ Type-X is equipped with intelligent functions such as follow-me, waypoint navigation and obstacle detection with Artificial Intelligence being part of the algorithms. With the Type-X Milrem Robotics also introduces a feature called Indirect Drive that allows remote controlled operations on higher speeds.

Milrem Robotics is the European leading robotics and autonomous systems developer and systems integrator with offices in Estonia, Sweden, Finland and shortly in the Netherlands.

The company leads the iMUGS Consortium that was awarded 30,6 MEUR from the European Commission’s European Defence Industrial Development Programme (EDIDP) to develop a European standardized unmanned ground system (UGS).

Kongsberg Defence & Aerospace is a leading supplier of defence products and systems for command and control, surveillance, space, tactical communications, remote weapon stations and missiles, as well as advanced composites, engineering products and repair and overhaul services for aircraft and helicopters.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye